CERS6 and acute lymphoblastic leukemia: CCRF-CEM cells with CERS6 knockdown were sensitized to dexamethasone, part of ALL standard treatment, in comparison to control cells (32.5 ± 11.9% vs 2.2 ± 1.1% survival at 100 nM, p < 0.001, Supplemental Figs. S3b, c).